Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
NCT05180162Phase 1Completed
- Start
- Dec 2021
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial (3 cohorts). Primary endpoints: Proportion of participants with treatment-related adverse events at 31 days, Median peak standardized uptake value (SUVpeak) in liver region at 1 day and 2 more. Started Dec 2021; status: completed.
Beyond the preview
Go deeper on NCT05180162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05180162.